AstraZeneca PLC · AZN · FY2026 Q2 · Calendar Q3 2026
AstraZeneca posts EPS beat as revenue narrowly misses estimate
AstraZeneca’s supplied results show earnings resilience, with EPS above consensus and revenue slightly below it. The investment case remains dependent on pipeline execution, launches, and offsetting portfolio and pricing pressures.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about AZN FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current quarter delivered actual EPS of 2.63 versus 2.50 estimated and revenue of 15.384 billion versus 15.436 billion estimated. The supplied current-quarter transcript analysis was unavailable; prior-quarter analysis emphasized oncology and rare-disease growth, pipeline progress, and higher investment.
Guidance delta
A current-quarter guidance change is not available in the supplied analysis. Prior-quarter full-year guidance was described as maintained, with mid- to high-single-digit revenue growth and low double-digit EPS growth.
Key takeaways
- EPS exceeded the supplied consensus estimate, while revenue was slightly below estimate.
- The current transcript analysis was skipped because of a provider outage; no additional current-quarter management interpretation is supplied.
- Prior analysis highlighted oncology and rare-disease growth, pipeline readouts, and planned manufacturing and pipeline investment.
- The prior-quarter analysis identified portfolio, pricing, regulatory, and competitive pressures as risks.
Management priorities
- Advance the clinical pipeline and upcoming launches identified in the prior analysis.
- Expand manufacturing capacity and support pipeline investment.
- Build growth in oncology, rare disease, respiratory and immunology, and emerging markets.
Follow AZN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationAstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.…
Historical context
All AZN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the AZN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-28T23:41:33.134213+00:00
- FN2 earnings calendar · 2026-09-01T01:23:15.986970+00:00
- Polygon adjusted daily market bars · 2026-10-31T18:50:43.143244+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T18:50:43.140501+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.